Nina Ewald-Riegler
Papers
5
Total Citations
148
H-Index
5
About
Nina Ewald-Riegler is a gynecologic oncology researcher whose work has made significant contributions to our understanding of borderline ovarian tumors (BOT), a complex and relatively rare category of ovarian neoplasms. Operating within the framework of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study — one of the largest multicenter investigations into BOT — she has helped transform how clinicians approach diagnosis, staging, and patient management in this nuanced disease entity. Her most influential work, cited 75 times, examined age-dependent differences in clinical characteristics and outcomes among BOT patients, offering critical insights that help tailor treatment strategies across different patient populations. Her subsequent research on surgical staging underscored that incomplete staging carries negative prognostic implications, providing surgeons with evidence-based guidance on procedural thoroughness. Additional contributions exploring the diagnostic value of serum CA125 and the impact of BOT on patients' quality of life and sexual function reflect her commitment to holistic, patient-centered oncology research. Collectively accumulating nearly 150 citations, Ewald-Riegler's body of work has elevated the evidence base for BOT management beyond small retrospective trials, supporting more standardized, data-driven clinical practice in gynecologic oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary14 citations · 2015
- 4
- 5